α-Synuclein misfolding and Parkinson's disease

Chen, 1995, The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3–q22 and TaqI RFLP analysis, Genomics, 26, 425, 10.1016/0888-7543(95)80237-G

Maroteaux, 1988, Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal, J. Neurosci., 8, 2804, 10.1523/JNEUROSCI.08-08-02804.1988

Polymeropoulos, 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045, 10.1126/science.276.5321.2045

Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166

Zarranz, 2004, The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia, Ann. Neurol., 55, 164, 10.1002/ana.10795

Kruger, 1998, Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease, Nat. Genet., 18, 106, 10.1038/ng0298-106

Singleton, 2004, Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication, Brain, 127, 768, 10.1093/brain/awh081

Singleton, 2003, alpha-Synuclein locus triplication causes Parkinson's disease, Science, 302, 841, 10.1126/science.1090278

Farrer, 2004, Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications, Ann. Neurol., 55, 174, 10.1002/ana.10846

Spillantini, 1998, alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. U. S. A., 95, 6469, 10.1073/pnas.95.11.6469

Masliah, 2000, Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders, Science, 287, 1265, 10.1126/science.287.5456.1265

Feany, 2000, A Drosophila model of Parkinson's disease, Nature, 404, 394, 10.1038/35006074

Kuwahara, 2006, Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans, J. Biol. Chem., 281, 334, 10.1074/jbc.M504860200

Cao, 2005, Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans, J. Neurosci., 25, 3801, 10.1523/JNEUROSCI.5157-04.2005

Hamamichi, 2008, Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model, Proc. Natl. Acad. Sci. U. S. A., 105, 728, 10.1073/pnas.0711018105

Franssens, 2010, Yeast unfolds the road map toward alpha-synuclein-induced cell death, Cell Death Differ., 17, 746, 10.1038/cdd.2009.203

Desplats, 2009, Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein, Proc. Natl. Acad. Sci. U. S. A., 106, 13010, 10.1073/pnas.0903691106

Betarbet, 2000, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat. Neurosci., 3, 1301, 10.1038/81834

Trojanowski, 2003, Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses, Ann. N. Y. Acad. Sci., 991, 107, 10.1111/j.1749-6632.2003.tb07468.x

Goedert, 2001, Parkinson's disease and other alpha-synucleinopathies, Clin. Chem. Lab. Med., 39, 308, 10.1515/CCLM.2001.047

Dev, 2003, Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease, Neuropharmacology, 45, 14, 10.1016/S0028-3908(03)00140-0

Uversky, 2003, A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders, J. Biomol. Struct. Dyn., 21, 211, 10.1080/07391102.2003.10506918

Fink, 2006, The aggregation and fibrillation of alpha-synuclein, Acc. Chem. Res., 39, 628, 10.1021/ar050073t

Iwai, 1995, The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system, Neuron, 14, 467, 10.1016/0896-6273(95)90302-X

da Costa, 2000, Wild-type but not Parkinson's disease-related ala-53→Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli, J. Biol. Chem., 275, 24065, 10.1074/jbc.M002413200

Greten-Harrison, 2010, alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction, Proc. Natl. Acad. Sci. U. S. A., 107, 19573, 10.1073/pnas.1005005107

Uversky, 2008, Alpha-synuclein misfolding and neurodegenerative diseases, Curr. Protein Pept. Sci., 9, 507, 10.2174/138920308785915218

Payton, 2001, Protein–protein interactions of alpha-synuclein in brain homogenates and transfected cells, Brain Res. Mol. Brain Res., 95, 138, 10.1016/S0169-328X(01)00257-1

Weinreb, 1996, NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded, Biochemistry, 35, 13709, 10.1021/bi961799n

Uversky, 2001, Evidence for a partially folded intermediate in alpha-synuclein fibril formation, J. Biol. Chem., 276, 10737, 10.1074/jbc.M010907200

Uversky, 2002, Biophysical properties of human alpha-synuclein and its role in Parkinson's disease, 153

Lattman, 1994, Small angle X-ray scattering studies of protein folding, Curr. Opin. Struct. Biol., 4, 87, 10.1016/S0959-440X(94)90064-7

Kataoka, 1996, X-ray solution scattering studies of protein folding, Fold. Des., 1, R107, 10.1016/S1359-0278(96)00047-8

Semisotnov, 1996, Protein globularization during folding. A study by synchrotron small-angle X-ray scattering, J. Mol. Biol., 262, 559, 10.1006/jmbi.1996.0535

Kataoka, 1997, Structural characterization of the molten globule of alpha-lactalbumin by solution X-ray scattering, Protein Sci., 6, 422, 10.1002/pro.5560060219

Uversky, 1998, Anion-induced folding of Staphylococcal nuclease: characterization of multiple equilibrium partially folded intermediates, J. Mol. Biol., 278, 879, 10.1006/jmbi.1998.1741

Hagihara, 1998, Chain-like conformation of heat-denatured ribonuclease A and cytochrome c as evidenced by solution X-ray scattering, Fold. Des., 3, 195, 10.1016/S1359-0278(98)00027-3

Uversky, 1999, Natively unfolded human prothymosin alpha adopts partially folded collapsed conformation at acidic pH, Biochemistry, 38, 15009, 10.1021/bi990752+

Doniach, 2001, Changes in biomolecular conformation seen by small angle X-ray scattering, Chem. Rev., 101, 1763, 10.1021/cr990071k

Uversky, 2011, Intrinsically disordered proteins may escape unwanted interactions via functional misfolding, Biochim. Biophys. Acta, 1814, 693, 10.1016/j.bbapap.2011.03.010

Zhao, 2011, Structures of segments of α-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation, Protein Sci., 20, 996, 10.1002/pro.630

Eliezer, 2001, Conformational properties of alpha-synuclein in its free and lipid-associated states, J. Mol. Biol., 307, 1061, 10.1006/jmbi.2001.4538

Cho, 2007, Amino acid bulkiness defines the local conformations and dynamics of natively unfolded alpha-synuclein and tau, J. Am. Chem. Soc., 129, 3032, 10.1021/ja067482k

Allison, 2009, Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements, J. Am. Chem. Soc., 131, 18314, 10.1021/ja904716h

Salmon, 2010, NMR characterization of long-range order in intrinsically disordered proteins, J. Am. Chem. Soc., 132, 8407, 10.1021/ja101645g

Bertoncini, 2005, Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein, Proc. Natl. Acad. Sci. U. S. A., 102, 1430, 10.1073/pnas.0407146102

Bertoncini, 2005, Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation, J. Biol. Chem., 280, 30649, 10.1074/jbc.C500288200

Rao, 2010, A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins, J. Am. Chem. Soc., 132, 8657, 10.1021/ja100646t

Lee, 2007, Alpha-synuclein tertiary contact dynamics, J. Phys. Chem. B, 111, 2107, 10.1021/jp068604y

Dyson, 2005, Intrinsically unstructured proteins and their functions, Nat. Rev. Mol. Cell Biol., 6, 197, 10.1038/nrm1589

Uversky, 2011, Intrinsically disordered proteins from A to Z, Int. J. Biochem. Cell Biol., 43, 1090, 10.1016/j.biocel.2011.04.001

Bussell, 2001, Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein, J. Biol. Chem., 276, 45996, 10.1074/jbc.M106777200

Dedmon, 2005, Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations, J. Am. Chem. Soc., 127, 476, 10.1021/ja044834j

Fernandez, 2004, NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation, EMBO J., 23, 2039, 10.1038/sj.emboj.7600211

Zhou, 2010, Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions, Biochim. Biophys. Acta, 1802, 322, 10.1016/j.bbadis.2009.12.004

Ulmer, 2005, Structure and dynamics of micelle-bound human alpha-synuclein, J. Biol. Chem., 280, 9595, 10.1074/jbc.M411805200

De Genst, 2010, Structure and properties of a complex of alpha-synuclein and a single-domain camelid antibody, J. Mol. Biol., 402, 326, 10.1016/j.jmb.2010.07.001

Xie, 2010, Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication, FASEB J., 24, 196, 10.1096/fj.09-133082

Dunker, 2001, Intrinsically disordered protein, J. Mol. Graph. Model., 19, 26, 10.1016/S1093-3263(00)00138-8

Nelson, 2006, Recent atomic models of amyloid fibril structure, Curr. Opin. Struct. Biol., 16, 260, 10.1016/j.sbi.2006.03.007

Serag, 2002, Arrangement of subunits and ordering of beta-strands in an amyloid sheet, Nat. Struct. Biol., 9, 734, 10.1038/nsb838

Elam, 2003, Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS, Nat. Struct. Biol., 10, 461, 10.1038/nsb935

Ivanova, 2004, An amyloid-forming segment of beta 2-microglobulin suggests a molecular model for the fibril, Proc. Natl. Acad. Sci. U. S. A., 101, 10584, 10.1073/pnas.0403756101

Nelson, 2005, Structure of the cross-beta spine of amyloid-like fibrils, Nature, 435, 773, 10.1038/nature03680

Huntington, 1999, A 2.6A structure of a serpin polymer and implications for conformational disease, J. Mol. Biol., 293, 449, 10.1006/jmbi.1999.3184

Serpell, 2000, Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation, Proc. Natl. Acad. Sci. U. S. A., 97, 4897, 10.1073/pnas.97.9.4897

Sawaya, 2007, Atomic structures of amyloid cross-beta spines reveal varied steric zippers, Nature, 447, 453, 10.1038/nature05695

Vilar, 2008, The fold of alpha-synuclein fibrils, Proc. Natl. Acad. Sci. U. S. A., 105, 8637, 10.1073/pnas.0712179105

Heise, 2005, Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR, Proc. Natl. Acad. Sci. U. S. A., 102, 15871, 10.1073/pnas.0506109102

Orcellet, 2011, Structures behind the amyloid aggregation of alpha-synuclein: an NMR based approach, Curr. Protein Pept. Sci., 12, 188, 10.2174/138920311795860160

Uversky, 2007, Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation, J. Neurochem., 103, 17, 10.1111/j.1471-4159.2007.04764.x

Rochet, 2000, Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein, Biochemistry, 39, 10619, 10.1021/bi001315u

Wood, 1999, alpha-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease, J. Biol. Chem., 274, 19509, 10.1074/jbc.274.28.19509

Bhak, 2009, Granular assembly of alpha-synuclein leading to the accelerated amyloid fibril formation with shear stress, PLoS One, 4, e4177, 10.1371/journal.pone.0004177

Li, 2009, 19F NMR studies of alpha-synuclein conformation and fibrillation, Biochemistry, 48, 8578, 10.1021/bi900872p

Collins, 2004, Mechanism of prion propagation: amyloid growth occurs by monomer addition, PLoS Biol., 2, 1582, 10.1371/journal.pbio.0020321

Esler, 2000, Alzheimer's disease amyloid propagation by a template-dependent dock–lock mechanism, Biochemistry, 39, 6288, 10.1021/bi992933h

Chiti, 1999, Designing conditions for in vitro formation of amyloid protofilaments and fibrils, Proc. Natl. Acad. Sci. U. S. A., 96, 3590, 10.1073/pnas.96.7.3590

Giehm, 2011, Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation, Proc. Natl. Acad. Sci. U. S. A., 108, 3246, 10.1073/pnas.1013225108

Hong, 2011, Characterization of the non-fibrillar alpha-synuclein oligomers, Protein Pept. Lett., 18, 230, 10.2174/092986611794578332

Apetri, 2006, Secondary structure of alpha-synuclein oligomers: characterization by Raman and atomic force microscopy, J. Mol. Biol., 355, 63, 10.1016/j.jmb.2005.10.071

Glabe, 2008, Structural classification of toxic amyloid oligomers, J. Biol. Chem., 283, 29639, 10.1074/jbc.R800016200

Kayed, 2003, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science, 300, 486, 10.1126/science.1079469

Kayed, 2009, Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer, J. Biol. Chem., 284, 4230, 10.1074/jbc.M808591200

Kayed, 2007, Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers, Mol. Neurodegener., 2, 18, 10.1186/1750-1326-2-18

Luk, 2009, Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells, Proc. Natl. Acad. Sci. U. S. A., 106, 20051, 10.1073/pnas.0908005106

Conway, 1998, Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease, Nat. Med., 4, 1318, 10.1038/3311

Danzer, 2007, Different species of alpha-synuclein oligomers induce calcium influx and seeding, J. Neurosci., 27, 9220, 10.1523/JNEUROSCI.2617-07.2007

Kordower, 2008, Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease, Nat. Med., 14, 504, 10.1038/nm1747

Soto, 2011, Prion hypothesis: the end of the controversy?, Trends Biochem. Sci., 36, 151, 10.1016/j.tibs.2010.11.001

Lee, 2011, Protein aggregate spreading in neurodegenerative diseases: problems and perspectives, Neurosci. Res., 10.1016/j.neures.2011.05.008

Lundvig, 2005, Pathogenic effects of alpha-synuclein aggregation, Brain Res. Mol. Brain Res., 134, 3, 10.1016/j.molbrainres.2004.09.001

Brown, 2010, Oligomeric alpha-synuclein and its role in neuronal death, IUBMB Life, 62, 334, 10.1002/iub.316

Auluck, 2010, alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease, Annu. Rev. Cell Dev. Biol., 26, 211, 10.1146/annurev.cellbio.042308.113313

van Rooijen, 2010, Membrane permeabilization by oligomeric alpha-synuclein: in search of the mechanism, PLoS One, 5, e14292, 10.1371/journal.pone.0014292

van Rooijen, 2010, Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease, Curr. Protein Pept. Sci., 11, 334, 10.2174/138920310791330659

Volles, 2003, Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease, Biochemistry, 42, 7871, 10.1021/bi030086j

Kayed, 2004, Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases, J. Biol. Chem., 279, 46363, 10.1074/jbc.C400260200

Bennett, 2005, The role of alpha-synuclein in neurodegenerative diseases, Pharmacol. Ther., 105, 311, 10.1016/j.pharmthera.2004.10.010

Li, 2002, Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T, Neurotoxicology, 23, 553, 10.1016/S0161-813X(02)00066-9

Li, 2001, Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein, Biochemistry, 40, 11604, 10.1021/bi010616g

Conway, 2000, Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy, Proc. Natl. Acad. Sci. U. S. A., 97, 571, 10.1073/pnas.97.2.571

Conway, 2000, Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants, Ann. N. Y. Acad. Sci., 920, 42, 10.1111/j.1749-6632.2000.tb06903.x

Lansbury, 1999, Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease, Proc. Natl. Acad. Sci. U. S. A., 96, 3342, 10.1073/pnas.96.7.3342

Lashuel, 2002, Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils, J. Mol. Biol., 322, 1089, 10.1016/S0022-2836(02)00735-0

Lashuel, 2002, Neurodegenerative disease: amyloid pores from pathogenic mutations, Nature, 418, 291, 10.1038/418291a

M.R. Cookson, The biochemistry of Parkinson's disease, Annu Rev Biochem, 74 (2005) 29–52.

Goldberg, 2000, Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?, Nat. Cell Biol., 2, E115, 10.1038/35041081

Xu, 2002, Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease, Nat. Med., 8, 600, 10.1038/nm0602-600

Gosavi, 2002, Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion, J. Biol. Chem., 277, 48984, 10.1074/jbc.M208194200

van der Putten, 2000, Neuropathology in mice expressing human alpha-synuclein, J. Neurosci., 20, 6021, 10.1523/JNEUROSCI.20-16-06021.2000

Lo Bianco, 2002, alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease, Proc. Natl. Acad. Sci. U. S. A., 99, 10813, 10.1073/pnas.152339799

Auluck, 2002, Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease, Science, 295, 865, 10.1126/science.1067389

Auluck, 2002, Pharmacological prevention of Parkinson disease in Drosophila, Nat. Med., 8, 1185, 10.1038/nm1102-1185

Winner, 2011, In vivo demonstration that alpha-synuclein oligomers are toxic, Proc. Natl. Acad. Sci. U. S. A., 108, 4194, 10.1073/pnas.1100976108

Clark, 2005, Posttranslational protein modifications, Crit. Care Med., 33, S407, 10.1097/01.CCM.0000191712.96336.51

Aebersold, 2001, Mass spectrometry in proteomics, Chem. Rev., 101, 269, 10.1021/cr990076h

Beyer, 2006, alpha-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers, Acta Neuropathol. (Berl.), 112, 237, 10.1007/s00401-006-0104-6

Okochi, 2000, Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein, J. Biol. Chem., 275, 390, 10.1074/jbc.275.1.390

Fujiwara, 2002, alpha-Synuclein is phosphorylated in synucleinopathy lesions, Nat. Cell Biol., 4, 160, 10.1038/ncb748

Chen, 2005, Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease, Nat. Neurosci., 8, 657, 10.1038/nn1443

Nishie, 2004, Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy, Acta Neuropathol., 107, 292, 10.1007/s00401-003-0811-1

Chung, 2001, Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease, Nat. Med., 7, 1144, 10.1038/nm1001-1144

Smith, 2005, Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells, J. Neurosci., 25, 5544, 10.1523/JNEUROSCI.0482-05.2005

Azeredo da Silveira, 2009, Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease, Hum. Mol. Genet., 18, 872

Lee, 2011, Enhanced phosphatase activity attenuates {alpha}-synucleinopathy in a mouse model, J. Neurosci., 31, 6963, 10.1523/JNEUROSCI.6513-10.2011

Paleologou, 2010, Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein–membrane interactions, J. Neurosci., 30, 3184, 10.1523/JNEUROSCI.5922-09.2010

Nakamura, 2002, Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases, FEBS Lett., 521, 190, 10.1016/S0014-5793(02)02861-2

Chen, 2009, Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation, J. Clin. Invest., 119, 3257

Ischiropoulos, 2003, Biological selectivity and functional aspects of protein tyrosine nitration, Biochem. Biophys. Res. Commun., 305, 776, 10.1016/S0006-291X(03)00814-3

Giasson, 2000, Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions, Science, 290, 985, 10.1126/science.290.5493.985

Norris, 2003, Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications, J. Biol. Chem., 278, 27230, 10.1074/jbc.M212436200

Paxinou, 2001, Induction of alpha-synuclein aggregation by intracellular nitrative insult, J. Neurosci., 21, 8053, 10.1523/JNEUROSCI.21-20-08053.2001

Yamin, 2003, Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers, FEBS Lett., 542, 147, 10.1016/S0014-5793(03)00367-3

Hodara, 2004, Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation, J. Biol. Chem., 279, 47746, 10.1074/jbc.M408906200

Danielson, 2009, Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease, Anal. Chem., 81, 7823, 10.1021/ac901176t

Sevcsik, 2011, Allostery in a disordered protein: oxidative modifications to alpha-synuclein act distally to regulate membrane binding, J. Am. Chem. Soc., 133, 7152, 10.1021/ja2009554

Yu, 2010, Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats, PLoS One, 5, e9956, 10.1371/journal.pone.0009956

Souza, 2000, Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies, J. Biol. Chem., 275, 18344, 10.1074/jbc.M000206200

Conway, 2001, Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct, Science, 294, 1346, 10.1126/science.1063522

Glaser, 2005, Methionine oxidation, alpha-synuclein and Parkinson's disease, Biochim. Biophys. Acta, 1703, 157, 10.1016/j.bbapap.2004.10.008

Hokenson, 2004, Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein, Biochemistry, 43, 4621, 10.1021/bi049979h

Uversky, 2002, Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro, FEBS Lett., 517, 239, 10.1016/S0014-5793(02)02638-8

Yamin, 2003, Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein, J. Biol. Chem., 278, 27630, 10.1074/jbc.M303302200

Davies, 2005, The oxidative environment and protein damage, Biochim. Biophys. Acta, 1703, 93, 10.1016/j.bbapap.2004.08.007

Rekas, 2010, The structure of dopamine induced alpha-synuclein oligomers, Eur. Biophys. J., 39, 1407, 10.1007/s00249-010-0595-x

Leong, 2009, Modulation of alpha-synuclein aggregation by dopamine: a review, Neurochem. Res., 34, 1838, 10.1007/s11064-009-9986-8

Herrera, 2008, Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region, PLoS One, 3, e3394, 10.1371/journal.pone.0003394

Bisaglia, 2010, Dopamine quinones interact with alpha-synuclein to form unstructured adducts, Biochem. Biophys. Res. Commun., 394, 424, 10.1016/j.bbrc.2010.03.044

Lee, 2011, Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers, Exp. Mol. Med., 43, 216, 10.3858/emm.2011.43.4.026

Nonaka, 2005, Ubiquitination of alpha-synuclein, Biochemistry, 44, 361, 10.1021/bi0485528

Sampathu, 2003, Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies, Am. J. Pathol., 163, 91, 10.1016/S0002-9440(10)63633-4

Tofaris, 2003, Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function, J. Biol. Chem., 278, 44405, 10.1074/jbc.M308041200

Sakamoto, 2005, Progressive accumulation of ubiquitin and disappearance of alpha-synuclein epitope in multiple system atrophy-associated glial cytoplasmic inclusions: triple fluorescence study combined with Gallyas–Braak method, Acta Neuropathol., 110, 417, 10.1007/s00401-005-1066-9

Hejjaoui, 2011, Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson's disease with semisynthetic ubiquitinated alpha-synuclein, Angew. Chem. Int. Ed. Engl., 50, 405, 10.1002/anie.201005546

Rott, 2008, Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells, J. Biol. Chem., 283, 3316, 10.1074/jbc.M704809200

Haywood, 2004, Parkin counteracts symptoms in a Drosophila model of Parkinson's disease, BMC Neurosci., 5, 14, 10.1186/1471-2202-5-14

Yang, 2003, Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila, Neuron, 37, 911, 10.1016/S0896-6273(03)00143-0

Lee, 2009, The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease, J. Neurochem., 110, 208, 10.1111/j.1471-4159.2009.06124.x

Dorval, 2006, Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein, J. Biol. Chem., 281, 9919, 10.1074/jbc.M510127200

Oh, 2011, Human Polycomb protein 2 promotes alpha-synuclein aggregate formation through covalent SUMOylation, Brain Res., 1381, 78, 10.1016/j.brainres.2011.01.039

Bucala, 1992, Advanced glycosylation: chemistry, biology, and implications for diabetes and aging, Adv. Pharmacol., 23, 1, 10.1016/S1054-3589(08)60961-8

Munch, 2000, Crosslinking of alpha-synuclein by advanced glycation endproducts—an early pathophysiological step in Lewy body formation?, J. Chem. Neuroanat., 20, 253, 10.1016/S0891-0618(00)00096-X

Shaikh, 2008, Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation, J. Neurosci. Res., 86, 2071, 10.1002/jnr.21644

Chen, 2010, Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products, PLoS One, 5, e9052, 10.1371/journal.pone.0009052

Padmaraju, 2011, Role of advanced glycation on aggregation and DNA binding properties of alpha-synuclein, J. Alzheimers Dis., 24, 211, 10.3233/JAD-2011-101965

Esterbauer, 1991, Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes, Free Radic. Biol. Med., 11, 81, 10.1016/0891-5849(91)90192-6

Nasstrom, 2009, The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers, Biochem. Biophys. Res. Commun., 378, 872, 10.1016/j.bbrc.2008.12.005

Nasstrom, 2011, The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological, and functional properties, Free Radic. Biol. Med., 50, 428, 10.1016/j.freeradbiomed.2010.11.027

Qin, 2007, Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation, J. Biol. Chem., 282, 5862, 10.1074/jbc.M608126200

Siegel, 2007, The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation, Biochemistry, 46, 1503, 10.1021/bi061853s

Murray, 2007, Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins, J. Biol. Chem., 282, 9335, 10.1074/jbc.M608589200

Bieschke, 2006, Small molecule oxidation products trigger disease-associated protein misfolding, Acc. Chem. Res., 39, 611, 10.1021/ar0500766

Dudek, 1993, Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau, J. Neurochem., 61, 1159, 10.1111/j.1471-4159.1993.tb03636.x

Andringa, 2004, Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease, FASEB J., 18, 932, 10.1096/fj.03-0829fje

Junn, 2003, Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. U. S. A., 100, 2047, 10.1073/pnas.0438021100

Schmid, 2009, Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease, J. Biol. Chem., 284, 13128, 10.1074/jbc.M809067200

Nemes, 2009, Transglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies, J. Biol. Chem., 284, 27252, 10.1074/jbc.M109.033969

Segers-Nolten, 2008, Tissue transglutaminase modulates alpha-synuclein oligomerization, Protein Sci., 17, 1395, 10.1110/ps.036103.108

Li, 2005, Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations, Proc. Natl. Acad. Sci. U. S. A., 102, 2162, 10.1073/pnas.0406976102

Liu, 2005, Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation, Glycobiology, 15, 1320, 10.1093/glycob/cwj014

Anderson, 2006, Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease, J. Biol. Chem., 281, 29739, 10.1074/jbc.M600933200

Murray, 2003, Role of alpha-synuclein carboxy-terminus on fibril formation in vitro, Biochemistry, 42, 8530, 10.1021/bi027363r

Wu, 2008, Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation, J. Mol. Biol., 378, 1104, 10.1016/j.jmb.2008.03.017

Liu, 2005, A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease, J. Biol. Chem., 280, 22670, 10.1074/jbc.M501508200

Ulusoy, 2010, Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology, Eur. J. Neurosci., 32, 409, 10.1111/j.1460-9568.2010.07284.x

Periquet, 2007, Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo, J. Neurosci., 27, 3338, 10.1523/JNEUROSCI.0285-07.2007

Tofaris, 2006, Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1–120): implications for Lewy body disorders, J. Neurosci., 26, 3942, 10.1523/JNEUROSCI.4965-05.2006

Bradshaw, 1989, Protein translocation and turnover in eukaryotic cells, Trends Biochem. Sci., 14, 276, 10.1016/0968-0004(89)90063-7

Zabrocki, 2008, Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson, Biochim. Biophys. Acta, 1783, 1767, 10.1016/j.bbamcr.2008.06.010

Romero, 2001, Sequence complexity of disordered protein, Proteins, 42, 38, 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3

Obradovic, 2005, Exploiting heterogeneous sequence properties improves prediction of protein disorder, Proteins, 61, 176, 10.1002/prot.20735

Yang, 2005, RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteins, Bioinformatics, 21, 3369, 10.1093/bioinformatics/bti534

Dosztanyi, 2005, IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content, Bioinformatics, 21, 3433, 10.1093/bioinformatics/bti541

Zimmerman, 1991, Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli, J. Mol. Biol., 222, 599, 10.1016/0022-2836(91)90499-V

Fulton, 1982, How crowded is the cytoplasm?, Cell, 30, 345, 10.1016/0092-8674(82)90231-8

Yancey, 1982, Living with water stress: evolution of osmolyte systems, Science, 217, 1214, 10.1126/science.7112124

Ellis, 2001, Macromolecular crowding: obvious but underappreciated, Trends Biochem. Sci., 26, 597, 10.1016/S0968-0004(01)01938-7

Minton, 2001, The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media, J. Biol. Chem., 276, 10577, 10.1074/jbc.R100005200

Engel, 2008, Macromolecular crowding compacts unfolded apoflavodoxin and causes severe aggregation of the off-pathway intermediate during apoflavodoxin folding, J. Biol. Chem., 283, 27383, 10.1074/jbc.M802393200

Dhar, 2010, Structure, function, and folding of phosphoglycerate kinase are strongly perturbed by macromolecular crowding, Proc. Natl. Acad. Sci. U. S. A., 107, 17586, 10.1073/pnas.1006760107

Minton, 2000, Implications of macromolecular crowding for protein assembly, Curr. Opin. Struct. Biol., 10, 34, 10.1016/S0959-440X(99)00045-7

Morar, 2001, Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c, Protein Sci., 10, 2195, 10.1110/ps.24301

Mukherjee, 2009, Effect of dehydration on the aggregation kinetics of two amyloid peptides, J. Phys. Chem. B, 113, 531, 10.1021/jp809817s

Zhou, 2009, Crowded cell-like environment accelerates the nucleation step of amyloidogenic protein misfolding, J. Biol. Chem., 284, 30148, 10.1074/jbc.M109.002832

Phillip, 2009, Common crowding agents have only a small effect on protein–protein interactions, Biophys. J., 97, 875, 10.1016/j.bpj.2009.05.026

Nguyen, 2005, Evolutionary optimization of fluorescent proteins for intracellular FRET, Nat. Biotechnol., 23, 355, 10.1038/nbt1066

Sukenik, 2011, Crowding alone cannot account for cosolute effect on amyloid aggregation, PLoS One, 6, e15608, 10.1371/journal.pone.0015608

Uversky, 2002, Accelerated alpha-synuclein fibrillation in crowded milieu, FEBS Lett., 515, 99, 10.1016/S0014-5793(02)02446-8

Shtilerman, 2002, Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?, Biochemistry, 41, 3855, 10.1021/bi0120906

Munishkina, 2008, Concerted action of metals and macromolecular crowding on the fibrillation of alpha-synuclein, Protein Pept. Lett., 15, 1079, 10.2174/092986608786071102

Munishkina, 2004, The effect of macromolecular crowding on protein aggregation and amyloid fibril formation, J. Mol. Recognit., 17, 456, 10.1002/jmr.699

Munishkina, 2008, Guiding protein aggregation with macromolecular crowding, Biochemistry, 47, 8993, 10.1021/bi8008399

Munishkina, 2009, Accelerated fibrillation of alpha-synuclein induced by the combined action of macromolecular crowding and factors inducing partial folding, Curr. Alzheimer Res., 6, 252, 10.2174/156720509788486491

Munishkina, 2004, Role of protein–water interactions and electrostatics in alpha-synuclein fibril formation, Biochemistry, 43, 3289, 10.1021/bi034938r

Tanner, 1989, Environmental factors and Parkinson's disease: a case–control study in China, Neurology, 39, 660, 10.1212/WNL.39.5.660

Tanner, 1989, The role of environmental toxins in the etiology of Parkinson's disease, Trends Neurosci., 12, 49, 10.1016/0166-2236(89)90135-5

Di Monte, 2003, The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?, Lancet Neurol., 2, 531, 10.1016/S1474-4422(03)00501-5

McCormack, 2002, Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat, Neurobiol. Dis., 10, 119, 10.1006/nbdi.2002.0507

Di Monte, 2002, Environmental factors in Parkinson's disease, Neurotoxicology, 23, 487, 10.1016/S0161-813X(02)00099-2

Di Monte, 2001, The role of environmental agents in Parkinson's disease, Clin. Neurosci. Res., 1, 419, 10.1016/S1566-2772(01)00020-2

Uversky, 2004, Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration, Cell Tissue Res., 318, 225, 10.1007/s00441-004-0937-z

Tanner, 2011, Rotenone, paraquat, and Parkinson's disease, Environ. Health Perspect., 119, 866, 10.1289/ehp.1002839

Manning-Bog, 2002, The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein, J. Biol. Chem., 277, 1641, 10.1074/jbc.C100560200

Sherer, 2003, Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation, Exp. Neurol., 179, 9, 10.1006/exnr.2002.8072

Inden, 2011, Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice, Biol. Pharm. Bull., 34, 92, 10.1248/bpb.34.92

Uversky, 2002, Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease, Neurotoxicology, 23, 527, 10.1016/S0161-813X(02)00067-0

Uversky, 2001, Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease, FEBS Lett., 500, 105, 10.1016/S0014-5793(01)02597-2

Gorell, 1999, Occupational metal exposures and the risk of Parkinson's disease, Neuroepidemiology, 18, 303, 10.1159/000026225

Gorell, 1999, Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease, Neurotoxicology, 20, 239

Altschuler, 1999, Aluminum-containing antacids as a cause of idiopathic Parkinson's disease, Med. Hypotheses, 53, 22, 10.1054/mehy.1997.0701

Zayed, 1990, Environmental factors in the etiology of Parkinson's disease, Can. J. Neurol. Sci., 17, 286, 10.1017/S0317167100030584

Zayed, 1990, Parkinson disease and environmental factors, Rev. Epidemiol. Sante. Publique, 38, 159

Rybicki, 1993, Parkinson's disease mortality and the industrial use of heavy metals in Michigan, Mov. Disord., 8, 87, 10.1002/mds.870080116

Gorell, 1997, Occupational exposures to metals as risk factors for Parkinson's disease, Neurology, 48, 650, 10.1212/WNL.48.3.650

Hirsch, 1991, Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis, J. Neurochem., 56, 446, 10.1111/j.1471-4159.1991.tb08170.x

Riederer, 1989, Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains, J. Neurochem., 52, 515, 10.1111/j.1471-4159.1989.tb09150.x

Dexter, 1991, Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia, Brain, 114, 1953, 10.1093/brain/114.4.1953

Dexter, 1989, Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease, J. Neurochem., 52, 1830, 10.1111/j.1471-4159.1989.tb07264.x

Boudreau, 2009, The association of metal ion exposure with alpha-synuclein-like immunoreactivity in the central nervous system of fish, Catostomus commersoni, Aquat. Toxicol., 92, 258, 10.1016/j.aquatox.2009.02.011

Oestreicher, 1994, Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study, Brain Res., 660, 8, 10.1016/0006-8993(94)90833-8

Kienzl, 1995, The role of transition metals in the pathogenesis of Parkinson's disease, J. Neurol. Sci., 134, 69, 10.1016/0022-510X(95)00210-S

Montgomery, 1995, Heavy metals and the etiology of Parkinson's disease and other movement disorders, Toxicology, 97, 3, 10.1016/0300-483X(94)02962-T

Bush, 2000, Metals and neuroscience, Curr. Opin. Chem. Biol., 4, 184, 10.1016/S1367-5931(99)00073-3

Santner, 2010, Metalloproteomics and metal toxicology of alpha-synuclein, Metallomics, 2, 378, 10.1039/b926659c

Paik, 1999, Copper(II)-induced self-oligomerization of alpha-synuclein, Biochem. J., 340, 821, 10.1042/0264-6021:3400821

Uversky, 2001, Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure, J. Biol. Chem., 276, 44284, 10.1074/jbc.M105343200

Goto, 1989, Conformational states of beta-lactamase: molten-globule states at acidic and alkaline pH with high salt, Biochemistry, 28, 945, 10.1021/bi00429a004

Goto, 1990, Mechanism of acid-induced folding of proteins, Biochemistry, 29, 3480, 10.1021/bi00466a009

Goto, 1990, Acid-induced folding of proteins, Proc. Natl. Acad. Sci. U. S. A., 87, 573, 10.1073/pnas.87.2.573

Fink, 1994, Classification of acid denaturation of proteins: intermediates and unfolded states, Biochemistry, 33, 12504, 10.1021/bi00207a018

Paik, 1997, Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid, Arch. Biochem. Biophys., 344, 325, 10.1006/abbi.1997.0207

Ly, 2008, Protein–metal interactions of calmodulin and alpha-synuclein monitored by selective noncovalent adduct protein probing mass spectrometry, J. Am. Soc. Mass Spectrom., 19, 1663, 10.1016/j.jasms.2008.07.006

Khan, 2005, Metals accelerate the formation and direct the structure of amyloid fibrils of NAC, J. Inorg. Biochem., 99, 1920, 10.1016/j.jinorgbio.2005.06.018

Kostka, 2008, Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers, J. Biol. Chem., 283, 10992, 10.1074/jbc.M709634200

Hettiarachchi, 2009, alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells, J. Neurochem., 111, 1192, 10.1111/j.1471-4159.2009.06411.x

Mosharov, 2009, Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons, Neuron, 62, 218, 10.1016/j.neuron.2009.01.033

Nielsen, 2001, Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization, J. Biol. Chem., 276, 22680, 10.1074/jbc.M101181200

Lowe, 2004, Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain, Protein Sci., 13, 3245, 10.1110/ps.04879704

Nath, 2011, Raised calcium promotes alpha-synuclein aggregate formation, Mol. Cell. Neurosci., 46, 516, 10.1016/j.mcn.2010.12.004

Pountney, 2004, Annular alpha-synuclein species from purified multiple system atrophy inclusions, J. Neurochem., 90, 502, 10.1111/j.1471-4159.2004.02533.x

Pountney, 2005, Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy, Hypothesis, Neurotox. Res., 7, 59, 10.1007/BF03033776

Tamamizu-Kato, 2006, Calcium-triggered membrane interaction of the alpha-synuclein acidic tail, Biochemistry, 45, 10947, 10.1021/bi060939i

Rasia, 2005, Structural characterization of copper(II) binding to alpha-synuclein: insights into the bioinorganic chemistry of Parkinson's disease, Proc. Natl. Acad. Sci. U. S. A., 102, 4294, 10.1073/pnas.0407881102

Binolfi, 2011, Exploring the structural details of Cu(I) binding to alpha-synuclein by NMR spectroscopy, J. Am. Chem. Soc., 133, 194, 10.1021/ja107842f

Bharathi, 2007, Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study, Neurosci. Lett., 424, 78, 10.1016/j.neulet.2007.06.052

Dudzik, 2011, Coordination features and affinity of the Cu(2)+ site in the alpha-synuclein protein of Parkinson's disease, Biochemistry, 50, 1771, 10.1021/bi101912q

Davies, 2011, Alpha-synuclein is a cellular ferrireductase, PLoS One, 6, e15814, 10.1371/journal.pone.0015814

Lee, 2008, Copper(II) binding to alpha-synuclein, the Parkinson's protein, J. Am. Chem. Soc., 130, 6898, 10.1021/ja711415b

Drew, 2008, Cu2+ binding modes of recombinant alpha-synuclein—insights from EPR spectroscopy, J. Am. Chem. Soc., 130, 7766, 10.1021/ja800708x

Bortolus, 2010, Structural characterization of a high affinity mononuclear site in the copper(II)–alpha-synuclein complex, J. Am. Chem. Soc., 132, 18057, 10.1021/ja103338n

Davies, 2011, The synucleins are a family of redox-active copper binding proteins, Biochemistry, 50, 37, 10.1021/bi101582p

Jackson, 2009, Identification of the minimal copper(II)-binding alpha-synuclein sequence, Inorg. Chem., 48, 9303, 10.1021/ic901157w

Sung, 2006, NMR mapping of copper binding sites in alpha-synuclein, Biochim. Biophys. Acta, 1764, 5, 10.1016/j.bbapap.2005.11.003

Sandal, 2008, Conformational equilibria in monomeric alpha-synuclein at the single-molecule level, PLoS Biol., 6, e6, 10.1371/journal.pbio.0060006

Brown, 2009, Metal binding to alpha-synuclein peptides and its contribution to toxicity, Biochem. Biophys. Res. Commun., 380, 377, 10.1016/j.bbrc.2009.01.103

Lucas, 2010, Evidence for copper-dioxygen reactivity during alpha-synuclein fibril formation, J. Am. Chem. Soc., 132, 6636, 10.1021/ja101756m

Meloni, 2011, Redox activity of alpha-synuclein–Cu is silenced by Zn(7)-metallothionein-3, Free Radic. Biol. Med., 50, 1471, 10.1016/j.freeradbiomed.2011.02.003

Natalello, 2011, Compact conformations of alpha-synuclein induced by alcohols and copper, Proteins, 79, 611, 10.1002/prot.22909

Wright, 2009, Unique copper-induced oligomers mediate alpha-synuclein toxicity, FASEB J., 23, 2384, 10.1096/fj.09-130039

Tabner, 2002, Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease, Free Radic. Biol. Med., 32, 1076, 10.1016/S0891-5849(02)00801-8

Wolozin, 2002, Iron and Parkinson's disease, Neuroscientist, 8, 22, 10.1177/107385840200800107

Hillmer, 2010, Converse modulation of toxic alpha-synuclein oligomers in living cells by N′-benzylidene-benzohydrazide derivates and ferric iron, Biochem. Biophys. Res. Commun., 391, 461, 10.1016/j.bbrc.2009.11.080

Zuo, 2009, Potential role of alpha-synuclein and metallothionein in lead-induced inclusion body formation, Toxicol. Sci., 111, 100, 10.1093/toxsci/kfp132

Uitti, 1989, Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains, Can. J. Neurol. Sci., 16, 310, 10.1017/S0317167100029140

Yasui, 1992, Calcium, magnesium and aluminum concentrations in Parkinson's disease, Neurotoxicology, 13, 593

Bocca, 2006, Metal changes in CSF and peripheral compartments of parkinsonian patients, J. Neurol. Sci., 248, 23, 10.1016/j.jns.2006.05.007

Aden, 2011, Dietary intake and olfactory function in patients with newly diagnosed Parkinson's disease: a case–control study, Nutr. Neurosci., 14, 25, 10.1179/174313211X12966635733312

Miyake, 2011, Dietary intake of metals and risk of Parkinson's disease: a case–control study in Japan, J. Neurol. Sci., 306, 98, 10.1016/j.jns.2011.03.035

Oyanagi, 2006, Magnesium deficiency over generations in rats with special references to the pathogenesis of the Parkinsonism–dementia complex and amyotrophic lateral sclerosis of Guam, Neuropathology, 26, 115, 10.1111/j.1440-1789.2006.00672.x

Hoyer, 2002, Dependence of alpha-synuclein aggregate morphology on solution conditions, J. Mol. Biol., 322, 383, 10.1016/S0022-2836(02)00775-1

Golts, 2002, Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein, J. Biol. Chem., 277, 16116, 10.1074/jbc.M107866200

Andre, 2005, Effect of metals on herbicides–alpha-synuclein association: a possible factor in neurodegenerative disease studied by capillary electrophoresis, Electrophoresis, 26, 3256, 10.1002/elps.200500169

Hashimoto, 2008, Magnesium exerts both preventive and ameliorating effects in an in vitro rat Parkinson disease model involving 1-methyl-4-phenylpyridinium (MPP+) toxicity in dopaminergic neurons, Brain Res., 1197, 143, 10.1016/j.brainres.2007.12.033

Cotzias, 1958, Manganese in health and disease, Physiol. Rev., 38, 503, 10.1152/physrev.1958.38.3.503

Barbeau, 1984, Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias), Neurotoxicology, 5, 13

Bleecker, 1988, Parkinsonism: a clinical marker of exposure to neurotoxins, Neurotoxicol. Teratol., 10, 475, 10.1016/0892-0362(88)90011-6

Lucchini, 2009, From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure, Neuromolecular Med, 11, 311, 10.1007/s12017-009-8108-8

Peneder, 2011, Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice, Neuroscience, 180, 280, 10.1016/j.neuroscience.2011.02.017

Gitler, 2009, Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity, Nat. Genet., 41, 308, 10.1038/ng.300

Pifl, 2004, alpha-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter, Neurosci. Lett., 354, 34, 10.1016/j.neulet.2003.09.064

Prabhakaran, 2011, alpha-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-kappaB-mediated pathway, Toxicol. Mech. Methods, 21, 435, 10.3109/15376516.2011.560210

Lovell, 1998, Copper, iron and zinc in Alzheimer's disease senile plaques, J. Neurol. Sci., 158, 47, 10.1016/S0022-510X(98)00092-6

Kim, 2000, Structural changes in alpha-synuclein affect its chaperone-like activity in vitro, Protein Sci., 9, 2489, 10.1110/ps.9.12.2489

Binolfi, 2006, Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement, J. Am. Chem. Soc., 128, 9893, 10.1021/ja0618649

Binolfi, 2008, Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation, J. Am. Chem. Soc., 130, 11801, 10.1021/ja803494v

Lindersson, 2005, p25alpha stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies, J. Biol. Chem., 280, 5703, 10.1074/jbc.M410409200

Lindersson, 2004, alpha-Synuclein filaments bind the transcriptional regulator HMGB-1, Neuroreport, 15, 2735

Lindersson, 2004, Alpha-synuclein binding proteins

Eriksen, 2010, Regulation of dopamine transporter function by protein–protein interactions: new discoveries and methodological challenges, J. Neurochem., 113, 27, 10.1111/j.1471-4159.2010.06599.x

Jin, 2006, Identification of novel proteins interacting with both a-synuclein and DJ-1, Mol. Cell Proteomics

Jenco, 1998, Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins, Biochemistry, 37, 4901, 10.1021/bi972776r

Liu, 2002, The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility, Cell, 111, 209, 10.1016/S0092-8674(02)01012-7

Shimura, 2001, Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease, Science, 293, 263, 10.1126/science.1060627

Engelender, 1999, Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions, Nat. Genet., 22, 110, 10.1038/8820

Kawamata, 2001, Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations, J. Neurochem., 77, 929, 10.1046/j.1471-4159.2001.00301.x

Ribeiro, 2002, Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein, J. Biol. Chem., 277, 23927, 10.1074/jbc.M201115200

Ostrerova, 1999, alpha-Synuclein shares physical and functional homology with 14-3-3 proteins, J. Neurosci., 19, 5782, 10.1523/JNEUROSCI.19-14-05782.1999

Ryo, 2006, Prolyl-isomerase Pin1 accumulates in Lewy bodies of Parkinson disease and facilitates formation of alpha-synuclein inclusions, J. Biol. Chem., 281, 4117, 10.1074/jbc.M507026200

Rekas, 2004, Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity, J. Mol. Biol., 340, 1167, 10.1016/j.jmb.2004.05.054

Kaul, 2005, Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death, Brain Res. Mol. Brain Res., 139, 137, 10.1016/j.molbrainres.2005.05.022

Sung, 2001, Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein, J. Biol. Chem., 276, 27441, 10.1074/jbc.M101318200

Iwata, 2001, alpha-Synuclein forms a complex with transcription factor Elk-1, J. Neurochem., 77, 239, 10.1046/j.1471-4159.2001.t01-1-00232.x

Iwata, 2001, alpha-Synuclein affects the MAPK pathway and accelerates cell death, J. Biol. Chem., 276, 45320, 10.1074/jbc.M103736200

Yoshimoto, 1995, NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation, Proc. Natl. Acad. Sci. U. S. A., 92, 9141, 10.1073/pnas.92.20.9141

Jensen, 1997, Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC, Biochem. J., 323, 539, 10.1042/bj3230539

Kim, 2001, Multiple ligand interaction of alpha-synuclein produced various forms of protein aggregates in the presence of Abeta25–35, copper, and eosin, Brain Res., 908, 93, 10.1016/S0006-8993(01)02575-6

Jensen, 2000, Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments, J. Biol. Chem., 275, 21500, 10.1074/jbc.M000099200

Alim, 2002, Tubulin seeds alpha-synuclein fibril formation, J. Biol. Chem., 277, 2112, 10.1074/jbc.M102981200

Jensen, 1999, alpha-Synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356, J. Biol. Chem., 274, 25481, 10.1074/jbc.274.36.25481

Lee, 1998, Tau interacts with src-family non-receptor tyrosine kinases, J. Cell Sci., 111, 3167, 10.1242/jcs.111.21.3167

Ghee, 2000, Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex, J. Neurochem., 75, 2221, 10.1046/j.1471-4159.2000.0752221.x

Snyder, 2003, Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function, J. Biol. Chem., 278, 11753, 10.1074/jbc.M208641200

Ahn, 2002, alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells, J. Biol. Chem., 277, 12334, 10.1074/jbc.M110414200

Peng, 2005, Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells, J. Cell Sci., 118, 3523, 10.1242/jcs.02481

Torres, 2001, Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1, Neuron, 30, 121, 10.1016/S0896-6273(01)00267-7

Elkon, 2002, Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase, J. Mol. Neurosci., 18, 229, 10.1385/JMN:18:3:229

Perez, 2002, A role for alpha-synuclein in the regulation of dopamine biosynthesis, J. Neurosci., 22, 3090, 10.1523/JNEUROSCI.22-08-03090.2002

Tehranian, 2006, Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells, J. Neurochem., 99, 1188, 10.1111/j.1471-4159.2006.04146.x

Meulener, 2005, DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein, J. Neurochem., 93, 1524, 10.1111/j.1471-4159.2005.03145.x

Zhou, 2006, The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein, J. Mol. Biol., 356, 1036, 10.1016/j.jmb.2005.12.030

Goers, 2003, Nuclear localization of alpha-synuclein and its interaction with histones, Biochemistry, 42, 8465, 10.1021/bi0341152

Lee, 2002, alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes, J. Neurochem., 82, 1007, 10.1046/j.1471-4159.2002.01024.x

Martinez, 2003, Parkinson's disease-associated alpha-synuclein is a calmodulin substrate, J. Biol. Chem., 278, 17379, 10.1074/jbc.M209020200

Giasson, 2002, Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein, Neuron, 34, 521, 10.1016/S0896-6273(02)00682-7

Esteves, 2010, Microtubule depolymerization potentiates alpha-synuclein oligomerization, Front Aging Neurosci., 1, 5, 10.3389/neuro.24.005.2009

Morales, 2010, Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases, J. Neurosci., 30, 4528, 10.1523/JNEUROSCI.5924-09.2010

Mougenot, 2011, Transmission of prion strains in a transgenic mouse model overexpressing human A53T mutated alpha-synuclein, J. Neuropathol. Exp. Neurol., 70, 377, 10.1097/NEN.0b013e318217d95f

Waxman, 2011, Induction of intracellular tau aggregation is promoted by {alpha}-synuclein seeds and provides novel insights into the hyperphosphorylation of tau, J. Neurosci., 31, 7604, 10.1523/JNEUROSCI.0297-11.2011

Meuvis, 2010, The conformation and the aggregation kinetics of alpha-synuclein depend on the proline residues in its C-terminal region, Biochemistry, 49, 9345, 10.1021/bi1010927

Gerard, 2006, The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy, FASEB J., 20, 524, 10.1096/fj.05-5126fje

Calabrese, 2008, A regulatable switch mediates self-association in an immunoglobulin fold, Nat. Struct. Mol. Biol., 15, 965, 10.1038/nsmb.1483

Eichner, 2009, A generic mechanism of beta2-microglobulin amyloid assembly at neutral pH involving a specific proline switch, J. Mol. Biol., 386, 1312, 10.1016/j.jmb.2009.01.013

Shashidharan, 2000, Immunohistochemical localization and distribution of torsinA in normal human and rat brain, Brain Res., 853, 197, 10.1016/S0006-8993(99)02232-5

Shashidharan, 2000, TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease, Brain Res., 877, 379, 10.1016/S0006-8993(00)02702-5

Walker, 2001, Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain, Brain Res., 900, 348, 10.1016/S0006-8993(01)02302-2

McLean, 2002, TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation, J. Neurochem., 83, 846, 10.1046/j.1471-4159.2002.01190.x

Tetzlaff, 2008, CHIP targets toxic alpha-synuclein oligomers for degradation, J. Biol. Chem., 283, 17962, 10.1074/jbc.M802283200

Outeiro, 2006, Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation, Biochem. Biophys. Res. Commun., 351, 631, 10.1016/j.bbrc.2006.10.085

Lo Bianco, 2008, Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease, J. Clin. Invest., 118, 3087, 10.1172/JCI35781

Putcha, 2010, Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity, J. Pharmacol. Exp. Ther., 332, 849, 10.1124/jpet.109.158436

Pountney, 2005, Alpha B-crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy, Neurotox. Res., 7, 77, 10.1007/BF03033778

Klucken, 2004, Hsp70 reduces alpha-synuclein aggregation and toxicity, J. Biol. Chem., 279, 25497, 10.1074/jbc.M400255200

Danzer, 2011, Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity, FASEB J., 25, 326, 10.1096/fj.10-164624

Luk, 2008, Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly, Biochemistry, 47, 12614, 10.1021/bi801475r

Hinault, 2010, Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones, J. Biol. Chem., 285, 38173, 10.1074/jbc.M110.127753

Uversky, 2002, Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins, J. Biol. Chem., 277, 11970, 10.1074/jbc.M109541200

Hashimoto, 2001, beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor, Neuron, 32, 213, 10.1016/S0896-6273(01)00462-7

Israeli, 2009, Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein, J. Neurochem., 108, 465, 10.1111/j.1471-4159.2008.05776.x

Stefani, 2010, Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity, FEBS J., 277, 4602, 10.1111/j.1742-4658.2010.07889.x

Ladiwala, 2011, Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways, J. Biol. Chem., 286, 3209, 10.1074/jbc.M110.173856

Lee, 2011, Molecular structure of amyloid fibrils controls the relationship between fibrillar size and toxicity, PLoS One, 6, e20244, 10.1371/journal.pone.0020244

Necula, 2007, Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct, J. Biol. Chem., 282, 10311, 10.1074/jbc.M608207200

Necula, 2007, Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization, Biochemistry, 46, 8850, 10.1021/bi700411k

Ladiwala, 2011, Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid beta, ChemBioChem, 10.1002/cbic.201100123

Ladiwala, 2010, Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers, J. Biol. Chem., 285, 24228, 10.1074/jbc.M110.133108

Ehrnhoefer, 2008, EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers, Nat. Struct. Mol. Biol., 15, 558, 10.1038/nsmb.1437

Li, 2004, Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils, Chem. Biol., 11, 1513, 10.1016/j.chembiol.2004.08.025

Conway, 2000, Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid, Biochemistry, 39, 2552, 10.1021/bi991447r

Wu, 2001, Anti-HIV activity of medicinal herbs: usage and potential development, Am. J. Chin. Med., 29, 69, 10.1142/S0192415X01000083

Ikezoe, 2001, Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest, Prostate, 49, 285, 10.1002/pros.10024

Gao, 2001, Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells, Pharmacol. Res., 43, 173, 10.1006/phrs.2000.0761

Shieh, 2000, Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin, Anticancer. Res., 20, 2861

Zhu, 2004, The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils, J. Biol. Chem., 279, 26846, 10.1074/jbc.M403129200

Lu, 2011, Baicalein inhibits formation of alpha-synuclein oligomers within living cells and prevents Abeta peptide fibrillation and oligomerisation, ChemBioChem, 12, 615, 10.1002/cbic.201000604

Hong, 2008, Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein, J. Mol. Biol., 383, 214, 10.1016/j.jmb.2008.08.039

Bieschke, 2010, EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity, Proc. Natl. Acad. Sci. U. S. A., 107, 7710, 10.1073/pnas.0910723107

Wang, 2010, Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model, BMC Neurosci., 11, 57, 10.1186/1471-2202-11-57

Ono, 2008, Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders, Curr. Pharm. Des., 14, 3247, 10.2174/138161208786404191

Pandey, 2008, Curcumin inhibits aggregation of alpha-synuclein, Acta Neuropathol., 115, 479, 10.1007/s00401-007-0332-4

Meng, 2010, Effects of various flavonoids on the alpha-synuclein fibrillation process, Parkinsons Dis., 2010, 650794

Braga, 2011, The anti-Parkinsonian drug selegiline delays the nucleation phase of alpha-synuclein aggregation leading to the formation of nontoxic species, J. Mol. Biol., 405, 254, 10.1016/j.jmb.2010.10.027

Masuda, 2006, Small molecule inhibitors of alpha-synuclein filament assembly, Biochemistry, 45, 6085, 10.1021/bi0600749

Bodner, 2006, Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases, Proc. Natl. Acad. Sci. U. S. A., 103, 4246, 10.1073/pnas.0511256103

Bodner, 2006, New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions, Cell Cycle, 5, 1477, 10.4161/cc.5.14.2929

Hong, 2009, Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation?, Biochim. Biophys. Acta, 1794, 282, 10.1016/j.bbapap.2008.09.026

Ono, 2009, A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P+A53T transgenic mice, Parkinsonism Relat. Disord., 15, 649, 10.1016/j.parkreldis.2009.03.002

Inden, 2007, Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone, J. Neurochem., 101, 1491, 10.1111/j.1471-4159.2006.04440.x

Dang, 1999, c-Myc target genes involved in cell growth, apoptosis, and metabolism, Mol. Cell. Biol., 19, 1, 10.1128/MCB.19.1.1

Metallo, 2010, Intrinsically disordered proteins are potential drug targets, Curr. Opin. Chem. Biol., 14, 481, 10.1016/j.cbpa.2010.06.169

Hammoudeh, 2009, Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc, J. Am. Chem. Soc., 131, 7390, 10.1021/ja900616b

Yin, 2003, Low molecular weight inhibitors of Myc–Max interaction and function, Oncogene, 22, 6151, 10.1038/sj.onc.1206641

Wang, 2007, Improved low molecular weight Myc–Max inhibitors, Mol. Cancer Ther., 6, 2399, 10.1158/1535-7163.MCT-07-0005

Uren, 2004, Recombinant EWS-FLI1 oncoprotein activates transcription, Biochemistry, 43, 13579, 10.1021/bi048776q

Ng, 2007, Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins, Proc. Natl. Acad. Sci. U. S. A., 104, 479, 10.1073/pnas.0607007104

Erkizan, 2010, Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma, Clin. Cancer Res., 16, 4077, 10.1158/1078-0432.CCR-09-2261

Erkizan, 2009, A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma, Nat. Med., 15, 750, 10.1038/nm.1983

Segrest, 1990, Amphipathic helix motif: classes and properties, Proteins, 8, 103, 10.1002/prot.340080202

Segrest, 1992, The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function, J. Lipid. Res., 33, 141, 10.1016/S0022-2275(20)41536-6

Perrin, 2000, Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis, J. Biol. Chem., 275, 34393, 10.1074/jbc.M004851200

Davidson, 1998, Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes, J. Biol. Chem., 273, 9443, 10.1074/jbc.273.16.9443

McLean, 2000, Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations, J. Biol. Chem., 275, 8812, 10.1074/jbc.275.12.8812

Lee, 2002, Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form, J. Biol. Chem., 277, 671, 10.1074/jbc.M107045200

Jao, 2008, Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement, Proc. Natl. Acad. Sci. U. S. A., 105, 19666, 10.1073/pnas.0807826105

Lokappa, 2011, {alpha}-Synuclein populates both elongated and broken helix states on small unilamellar vesicles, J. Biol. Chem., 286, 21450, 10.1074/jbc.M111.224055

Madine, 2006, A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers, Biochemistry, 45, 5783, 10.1021/bi052151q

Kamp, 2006, Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles, J. Biol. Chem., 281, 9251, 10.1074/jbc.M512292200

Varkey, 2010, Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins, J. Biol. Chem., 285, 32486, 10.1074/jbc.M110.139576

Pandey, 2011, alpha-Synuclein-induced tubule formation in lipid bilayers, J. Phys. Chem. B, 115, 5886, 10.1021/jp1121917

Zhu, 2006, Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles, Biochemistry, 45, 8135, 10.1021/bi052584t

Necula, 2003, Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro, J. Biol. Chem., 278, 46674, 10.1074/jbc.M308231200

Zhu, 2003, The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation, J. Biol. Chem., 278, 40186, 10.1074/jbc.M305326200

Zhu, 2003, Lipid binding inhibits alpha-synuclein fibril formation, J. Biol. Chem., 278, 16873, 10.1074/jbc.M210136200

Perrin, 2001, Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins, J. Biol. Chem., 276, 41958, 10.1074/jbc.M105022200

Cole, 2002, Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein, J. Biol. Chem., 277, 6344, 10.1074/jbc.M108414200

Sharon, 2003, The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease, Neuron, 37, 583, 10.1016/S0896-6273(03)00024-2

Jo, 2000, alpha-Synuclein membrane interactions and lipid specificity, J. Biol. Chem., 275, 34328, 10.1074/jbc.M004345200

Jo, 2004, alpha-Synuclein–synaptosomal membrane interactions: implications for fibrillogenesis, Eur. J. Biochem., 271, 3180, 10.1111/j.1432-1033.2004.04250.x

Ramakrishnan, 2006, Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR, Biochemistry, 45, 3386, 10.1021/bi052344d

Abedini, 2009, A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides, Protein Eng. Des. Sel., 22, 453, 10.1093/protein/gzp036

Abedini, 2009, A role for helical intermediates in amyloid formation by natively unfolded polypeptides?, Phys. Biol., 6, 015005, 10.1088/1478-3975/6/1/015005

Haque, 2010, Adsorption of alpha-synuclein on lipid bilayers: modulating the structure and stability of protein assemblies, J. Phys. Chem. B, 114, 4070, 10.1021/jp1006704

Golbe, 1990, The genetics of Parkinson's disease: a reconsideration, Neurology, 40, 7

Wood, 1998, Genetic risk factors in Parkinson's disease, Ann. Neurol., 44, S58, 10.1002/ana.410440709

Olanow, 1999, Etiology and pathogenesis of Parkinson's disease, Annu. Rev. Neurosci., 22, 123, 10.1146/annurev.neuro.22.1.123

El-Agnaf, 1998, Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease, FEBS Lett., 440, 67, 10.1016/S0014-5793(98)01419-7

Narhi, 1999, Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation, J. Biol. Chem., 274, 9843, 10.1074/jbc.274.14.9843

Giasson, 1999, Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro, J. Biol. Chem., 274, 7619, 10.1074/jbc.274.12.7619

Greenbaum, 2005, The E46K mutation in alpha-synuclein increases amyloid fibril formation, J. Biol. Chem., 280, 7800, 10.1074/jbc.M411638200

Fredenburg, 2007, The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states, Biochemistry, 46, 7107, 10.1021/bi7000246

Rospigliosi, 2009, E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein, J. Mol. Biol., 388, 1022, 10.1016/j.jmb.2009.03.065

Sung, 2007, Residual structure, backbone dynamics, and interactions within the synuclein family, J. Mol. Biol., 372, 689, 10.1016/j.jmb.2007.07.008

Choi, 2004, Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein, FEBS Lett., 576, 363, 10.1016/j.febslet.2004.09.038

Dauer, 2003, Parkinson's disease: mechanisms and models, Neuron, 39, 889, 10.1016/S0896-6273(03)00568-3